After August 17, 2026, Novus Biologicals products and services will no longer be available on this website; you will access all products and services on rndsystems.com. Create your R&D Systems online account today.
This product is produced by and distributed for Abnova, a company based in Taiwan.
Alternate Names for RNA Polymerase II/POLR2A RNAi
DNA-directed RNA polymerase II largest subunit, RNA polymerase II 220 kdsubunit
DNA-directed RNA polymerase II subunit A
DNA-directed RNA polymerase II subunit RPB1
DNA-directed RNA polymerase III largest subunit
EC 2.7.7.48
EC 2.7.7.6
hRPB220
hsRPB1
MGC75453
POLR2
POLR2A
POLRA
polymerase (RNA) II (DNA directed) polypeptide A (220kD)
polymerase (RNA) II (DNA directed) polypeptide A, 220kDa
RNA Pol 2
RNA Polymerase 2
RNA polymerase II subunit B1
RNA Polymerase II
RNA-directed RNA polymerase II subunit RPB1
RNAPII
RPB1
RPBh1
RpIILS
RPO2
RPOL2
Background
Chimera RNA interference (chimera RNAi) is process by which small interfering RNA/DNA chimera triggers the destruction of mRNA for the original gene. The discovery work, design, and application of chimera RNAi has been pioneered by Professor Kaoru Saigo and Dr. Kumiko Ui-Tei at the University of Tokyo. Chimera RNAi has many advantages over the conventional siRNAs. First, it has been demonstrated to have reliable knock-down for over 10,000 human genes. Because the human genome is composed of an intricate, genetic network, chimera RNAi's unique design has successfully obviated the off-target effects including microRNA-based influence. Another advantage of the chimera RNAi technology is its effectiveness at low concentrations (0.5nM to 5nM); only mRNA is destroyed so genomic genes are not affected. Finally, having both the sense and anti-sense strands consisting RNA/DNA chimera, it offers much greater compound stability for streamlining in vitro and in vivo assays and applications while minimizing interferon induction and other adverse reactions.
Limitations
This product is for research use only and is not approved for use in humans or in clinical diagnosis. RNAi are guaranteed for 3 months from date of receipt.